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Despite the lack of good quality evidence on this field,
there seems to be a growing interest in the internatio -
nal scientific community with several ongoing studies
promoting such interventions. This promising data will
be very useful to set up effective policies.
Conclusions: This article summarizes the current
knowledge about the impact of interventions to avoid
or mitigate early retirement in RD patients. It highlights
the demand for further research and it also contributes
to aware decision-makers about the relevance of this
topic, particularly in Portugal.
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INTRODUCTION
The world has continued to observe an increase in the
life expectancy1. The old-age dependency ratio is rising
steadily in most western countries, which are current-
ly facing a growing economically dependent elderly
population2. In Portugal, for instance, in 1980 there
were a total of 1.8 million pensions with a ratio of 4
acti ve age people per each Social Security old-age pen-
sioner, but now there are over 3.6 millions pensions
(including both the Social Security System and the Pu -
blic Administration Retirement Fund) and a ratio of
2.63. Life expectancy at 65 was 13.5 years in 1980,
while now it is 19.1 years4. Despite the recent overall
increase in the me dian retirement age, it has been in-
creasing at a much slo wer pace than life expectancy,
which leads to sustainability problems that will force all
countries to take action sooner or later. In fact, a trend
with early exit from employment is hardly feasible and
provides a major challenge to social and health poli-
cies. In particular, Portugal is already among the oldest
countries in the world, with one of the highest old-age
dependency ratios and it is at the forefront of this ge -
neral problem regarding premature work withdrawal2.
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ABSTRACT
Introduction: Aging of the population and early re-
tirement translates into productivity losses to society.
Persistence of working life is crucial to counteract this
sustainability issue faced by western countries. Mus-
culoskeletal and rheumatic diseases (RD) may cause
work disability and early exit from work, including ear-
ly retirement. The objective of this article is to review
the current knowledge about interventions aiming to
reduce early retirement due to RD.
Methods:We searched PubMed and The Cochrane Li-
brary for studies either in English or Portuguese be-
tween January 2000 and June 2016 that evaluated the
impact of interventions targeting early retirement in RD
patients still at work. We also searched for grey litera-
ture from Portuguese institutional repositories.
Results: We identified several published studies tes -
ting pharmacologic and non-pharmacologic vocatio -
nal rehabilitation interventions. None was specifically
identified for Portugal. The general low quality of the
literature and its inconsistency makes it unfeasible to
draw definitive conclusions. However, some broad re -
commendations might be outlined. An effective inter-
vention must: 1) act upon different levels (e.g. RD pa-
tient, workplace), involving several stakeholders (e.g.
rheumatologists, occupational physicians, employers);
2) prioritize the right patients (e.g. more disabling RD);
and 3) consider the patients’ role, for instance by in-
cluding an element of patient education and support.
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Musculoskeletal and Rheumatic Diseases (RD) are
highly prevalent in the western world and their clini-
cal and functional impacts may be profound, repre-
senting major causes of disability among workers. In
fact, RD may cause work disability and early exit from
work, including early retirement5-16.
RD usually generates pain and impairment, which
in turn may lead to disability and ultimately to work
disability and withdrawal (Figure 1 – Etiological mo -
del). In each step of this etiological model there are in-
fluencing factors, at least some of which may be
changeable to some extent (e.g. pain control and disea -
se activity). Interventions aiming to prevent RD-rela -
ted job loss should target at least some step of this mo -
del, therefore its comprehension is crucial in this field. 
The objective of this article is to review the current
knowledge about interventions aiming to reduce ear-
ly retirement due to RD.
METHODS
The information source used was PubMed, maintained
by the US National Library of Medicine, and The
Cochrane Library (including The Cochrane Database
of Systematic Reviews, Cochrane Central Register of
Controlled Trials, Database of Abstracts of Reviews of
Effects, Health Technology Assessment Database). We
searched for studies either in English or Portuguese
between January 2000 and June 2016, combining re -
levant keywords, such as “retirement”, “job loss”, “job
retention”, “exit from work”, “work participation”,
“employment status”, “sick leave”, “work disability”,
“rheumatic diseases”, “musculoskeletal diseases” and
“arthritis”. We also searched for grey literature from
Portuguese institutional repositories. The objectives of
this search were specified by the following framework:
Population – RD adults still at work who experience,
or are likely to experience, disability; Intervention –
Any vocational rehabilitation intervention (pharma-
cologic and non-pharmacologic); Comparison – any
or other intervention (including the standard practice);
Outcomes – early exit from work, including early re-
tirement.
RESULTS
Our article focuses on studies aiming to prevent em-
ployment loss (i.e. acting on the earlier steps of the
etio logical model) and we grouped the studies ac-
cording with the main nature of the intervention ap-
proach (i.e. pharmacologic and non-pharmacologic). 
PHARMACOLOGIC INTERVENTIONS
Below are some of the studies we found that tested the
impact of pharmacologic interventions on early exit
from work, including early retirement:
• In 2003, Yellin E et al. interviewed 497 American
RA patients of working age (18–64 years) about
Age, gender, genetics,lifestyle, other risk factors
Early and effective treatmentto decrease disease activity/pain/impairment
Impairment may becorrected by medicines,aids or appliances
Funcional limitations may becorrected by offsettingcapacities
(e.g. job accomodation) EARLYRETIREMENT
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FIGURE 1. Etiological model on the relationship between RD and Early Retirement (Adapted from Nagi S17 and Stattin M 200518)
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ciated with the reduction of self-reported em -
ployment loss. However, these results might be ham -
pered by a number of limitations, including the
study design (non-randomized) and the study popu -
lation (<61 years old)23.
• In 2008, Allaire S et al. using a nested, matched,
case–control approach in a large cohort of rheuma-
toid arthritis patients (NDB) observed no protection
of anti-TNF therapy against any or disease-attribu ted
employment loss. However, a protective effect was
found for users with shorter disease duration (<11
years. OR 0.4, 95% CI 0.2-0.9)24.
• In the same year, Cole JC and colleagues, re-exami -
ned data from 2 clinical trials [one for RA methotrex-
ate failure patients (n=652) and another for RA se-
vere anti-TNF failure patients (n=391)] and found a
significant reduction in the likelihood for early exit
from work with abatacept treatment compared with
placebo (at 6 months, 1 year and 2 years)25.
• Also in 2008, Bejarano V et al. published results
from a randomized controlled trial (RCT) reporting
positive results on reduced employment loss for a
56-weeks period following treatment with adali-
mumab plus methotrexate26.
• Similarly, a year later, Halpern MT et al. have shown
in an open label extension study that patients with
RA who received adalimumab experienced consi -
derably longer periods of work and continuous em-
ployment. Thus, during a 24-month period, 158 pa-
tients who received adalimumab worked 2 months
longer (95% CI 1.3-2.6) and were significantly less
likely to stop working than did the 180 patients
treated with DMARDs (HR 0.36, 95% CI 0.15-
-0.85)27.
• In 2010, Augustsson J et al. using data from the
Stockholm anti-TNF follow-up registry concluded
that biological therapy is associated with increases in
workforce participation in patients with RA28. Simi -
lar results have been obtained in another Swedish
register for ankylosing spondylitis29.
• In the same year, Verstappen SM et al. using a large
British RD registry (BSRBR, British Society for
Rheumatology Biologics Register) found that com-
pared with the use of conventional DMARDs, the
use of anti-TNF did not prevent patients with RA
(n=3291) from not working due to ill health/disa bi -
lity (adjusted OR 0.80; 95% CI 0.36-1.81; p=0.596).
However, RA patients in the anti-TNF group who
were in remission 6 months after commencing anti-
-TNF therapy were less likely to exit work 3 years 
their employment status in the year of diagnosis and
as of the study year. Among RA patients who had
been employed at the time of diagnosis, those from
the etanercept clinical trials were more likely to be
employed at the time of survey. Moreover, the au-
thors found that after adjustment for relevant fac-
tors having been in the etanercept clinical trials was
associated with higher employment rates9.
• In 2004, Puolakka K et al. analyzed the impact of
initial aggressive drug treatment with disease-mo -
difying anti-rheumatic drugs (DMARDs) versus
therapy with a single DMARD in the prevention of
work disability in patients with early RA. 195 pa-
tients were randomly assigned to receive either com-
bination therapy with DMARDs plus prednisolone
or single therapy with a DMARD with or without
prednisolone. After 2 years, the drug treatment stra -
tegy was no longer restricted. At baseline, 162 pa-
tients (80 in the combination-treatment group and
82 in the single-treatment group) were still working
or at least available for work. After 5 years of follow-
-up the authors found a positive impact with initial
aggressive drug treatment in terms of lost produ -
ctivity – including sick leave and employment loss,
either temporary (unemployment) or permanent
(disability pensions and retirement). However, this
benefit was mainly due to the differences in sick
leave. In fact, no statistically significant differences
were seen in the take-up of disability pensions or
early retirement20.
• In the same year, Kobelt G et al. observed a slight in-
crease in the work capacity (from 31% to 33%, based
on the proportion of patients on full time work) of
160 RA patients under 65 treated during the first
year with either etanercept or infliximab in four
rheumatology units in southern Sweden21.
• In 2006, Smolen JS et al. verified that the proportion
of patients whose status changed from employa ble
at baseline to unemployable at week 54 was smaller
in 722 RA patients receiving methotrexa te plus in-
fliximab compared with 282 RA patients receiving
methotrexate alone (8% versus 14%; p= 0.05)22.
• In 2007, Wolfe F et al. examined the effect of anti-
-TNF therapy on work disability using data from the
National Data Bank (NDB) for RD. They studied
3886 patients with RA who were employed at study
entry, of whom 1986 received and 1900 did not re-
ceive anti-TNF therapy. After adjustment for
demogra phics, RA severity, and comorbidity the au-
thors did not find that anti-TNF therapy was asso-
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after inclusion in the register30.
• Still in 2010, van Vollenhoven RF et al. showed that
the likelihood of gaining/ retaining employment over
2 years treatment in early RA patients was greater
for the combination therapy of abatacept plus
methotre xate (n=219) than for the methotrexate
alone (n=214. OR 1.53, 95% CI 1.04–2.26)31.
• In 2013, Eriksson JK et al. in a randomized con-
trolled open-label trial observed radiological supe-
riority of biological compared with conventional
combination therapy which did not translate into
better work loss outcomes (i.e. monthly sick leave
and disability pension days 21 months after ran-
domization) in patients with early RA who had ex-
perienced an insufficient response to methotrexate32.
• More recently, in 2016, the same author and col-
leagues compared the long-term employment loss
in methotrexate-refractory early RA patients ran-
domized to addition of infliximab or conventional
combination treatment. Of 210 working age pa-
tients, 109 were randomized to infliximab and 101
to conventional trea tment. After over 7 years of fol-
low-up in real world cli nical practice, the authors
observed that, compared to the year before ran-
domization, exit from employment of these patients
improved significantly, with the largest improvement
during the first 3 years. However, no difference was
detected between strategies, and the level of work
loss days remained twice that observed in the gene -
ral population33.
• In the same year, Olofsson T et al. using the Swedish
Biologics Register, after 5 years of follow-up, ob-
served a substantial decrease in work loss (i.e. mean
monthly days lost and accumulated employment
loss) of RA patients with high and moderate disease
activity treated with anti-TNF34.
Many other studies explored other work-related out-
comes (e.g. surrogate markers) in RD following phar-
macologic interventions35-50.
NON-PHARMACOLOGIC INTERVENTIONS
A vast amount of studies focused on non-pharmaco-
logic interventions aiming to facilitate return to work
after sickness absence of employees with low back pain.
However, there is already some data for other RD and
with other occupational outcomes as well, such as ear-
ly retirement. Below we listed the most relevant stu -
dies performed in this area (some studies also have a
pharmacologic intervention):
• In 2003, Allaire SH et al. made a RCT with 48
months of follow-up undertaken to determine the
efficacy of vocational rehabilitation, which consis -
ted of 3 components: job accommodation, vocatio -
nal counseling and guidance, and education and
self-advocacy. The job accommodation component
consisted of an assessment of possible health-rela ted
work place barriers to job performance and deve -
lopment of solutions to the barriers that participants
had identified. In the vocational counseling and
guidance component, the counselor and participant
evaluated the individual’s job in light of his or her
RD. If problems were foreseen, possible job alterna-
tives, requirements, and relevant resources were
identified. In the education and self-advocacy com-
ponent, information about legal rights and respon-
sibilities, guidance regarding disclosure issues, and
skills training to increase the participant’s ability to
request a job accommodation in an appropriate
manner were provided. The counselors also gave the
participants in the experimental group documenta-
tion about how to manage health-related employ-
ment problems and about other available resources.
A total of 242 patients with RD residing in Mas-
sachusetts, USA at risk for job loss were recruited,
122 for the experimental group and 120 for the con-
trol one. Employment withdrawal was delayed in
the experimental group compared with the control
group. After adjustment for potential confounders,
participation in the experimental group was found
to be protective against temporary or permanent
work loss (OR 0.58, 95% CI 0.34–0.99)51.
• In 2005, Abásolo L et al. analyzed the effect of a spe-
cific program, run by rheumatologists in Spain, in
which care was delivered during regular visits and
included 3 main elements: education, protocol-ba -
sed clinical management, and administrative duties.
Thus, the visits were structured following specific
proceedings for the different diagnoses, which inclu -
ded education (e.g. instructions about the diagnosed
RD and due self-management), pharmacologic and
non-pharmacologic treatment, and timing of diag-
nostic tests in a stepwise manner. 13,077 patients
were included in this RCT, 7805 in the control group
and 5272 in the intervention group. The program
was highly efficacious in several occupational outco -
mes. In particular, fewer participants in the inter-
vention group were permanently work disabled or
took early retirement after 4 years52,53.
• In 2005, de Buck PD et al. conducted a RCT within
the region of Leiden, the Netherlands, to investigate
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dividuals, in order to help them solve problems at
work. Participants were randomly assigned to the
intervention (N=64) or control group (N=58) and
after 24 months of follow-up no statistical diffe -
rences were observed regarding employment main-
tenance, which remained high in the whole group
resulting in too low power to show any significant
changes. Alike de Buck PD et al55 the authors obser -
ved less fatigue in the intervention group56.
The overall quality of these studies is low, namely
due to risk of bias, inconsistency and imprecision57,
which also highlights the need for further research on
this important topic. Other studies are currently on-
going to evaluate the effectiveness of specific interven-
tions on employment retention of RD patients58-59. 
On the other hand, some studies have already re-
ported the effect of non-pharmacologic interventions in
more temporary occupational outcomes, such as sick
leave60, or surrogate markers of early retirement, such
as assessments of function and work ability61-67. Some
scales have been developed specifically to measure
work ability in RD patients68.
DISCUSSION 
Many studies have been conducted about interventions
aiming to achieve successful outcomes in terms of re-
turn to work of workers with RD, however emphasis
has shifted towards employment maintenance rather
than the more likely irreversible exit from work. This
article focuses on interventions to avoid early retire-
ment while RD patients are still at work. There seems
to be more consistent data on the positive effects of
pharmacologic interventions than on the non-phar-
macologic ones. Many reasons may explain this, name-
ly the very nature of the interventions themselves. Non-
-pharmacologic activities vary immensely and its
effectiveness may be difficult to replicate in different
settings. Pharmacologic interventions may lower RD
activity and cease pain and impairment, which in turn
interfere with work disa bility and early retirement. It is
therefore of the utmost importance that RD patients are
effectively trea ted with the most appropriate pharma-
ceutical approach. Obvious ly, this judgment must al-
ways be done by the rheumatologist who needs to de-
cide on a case-by-case basis among the available
treatment options. On this regard, the current trend to
expand the rheumatology referral network in Portugal
may bring significant productivity gains by allowing
the effectiveness of a multidisciplinary job-retention
vocational rehabilitation program in RD patients at
risk for job loss, consisting of a systematic assess-
ment followed by education, vocational counseling,
guidance, and medical or non-medical treatment.
The program was delivered by a multidisciplinary
team comprising a rheumatologist, a social worker,
a physical therapist, an occupational therapist and a
psychologist. Depending on the specific problems
of the individual patient, the intervention further
consisted of education, counseling and guidance, or
treatment. All patients made at least 2 visits to the
hospital in connection with the job-retention voca-
tional rehabilitation program and the total duration
of the intervention varied, and lasted 4 to 12 weeks.
A total of 140 patients with a chronic rheumatic con-
dition were randomly assigned to either this voca-
tional rehabilitation program or usual outpatient
care. In contrast with the previous studies the au-
thors observed no difference between the 2 groups
regarding the proportion of patients having lost their
employment at any time point, with 24% and 23%
of the patients in the vocational rehabilitation pro-
gram and outpatient care groups, respectively, ha -
ving lost their work after 24 months. This could be
at least partly explained by the studied population
being composed by ~40% of patients already on sick
leave at baseline, many of them longer than 6 weeks.
Long-term sick leave usually indicates substantial
limitations in work capacity and often precedes per-
manent work disability. Of note, this study found
significant less fatigue in the intervention group,
which in turn is expected to lead to more employ-
ment maintenance in the long run54. The authors
emphasized that there was still plenty rationale for
the future development and evaluation of vocatio nal
rehabilitation programs, in particular the need for
early identification of RD patients at risk for work
disability, namely through the broad implementa-
tion in the clinical setting of rheumatologic care of
instruments to measure work disability55.
• In 2011, Varekamp I et al. studied the effect of an
employment maintenance program for employees
with chronic disease (25% with RD). This group-
-training program consisted of six three-hour ses-
sions every two weeks, with a seventh session two
months after the sixth. This was combined with
three individual counseling sessions. It had an em-
powerment perspective with the aim of enhancing
the knowle dge, self-awareness and skills of the in-
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the system to effectively address the problems systema -
tized in the etiologic model presented in this article and
thereby avoiding early retirement caused by RD. Un-
questionably, in order to ensure optimization of this
network, effective identification and referral of RD pa-
tients at risk of job loss requires alignment with the pri-
mary care (i.e. gene ral practitioner and occupational
physicians). 
Despite the overall inconsistence and low quality of
information, some studies have already shown promi -
sing results for the non-pharmacologic interventions.
For instance, the work done by Lydia Abásolo and col-
leagues52 is being highlighted by the Fit for Work Eu-
rope initiative, which produced estimates about the ef-
fects of repeating this intervention in other European
countries69. The ultimate occupational outcome from
successful interventions might be so large that justifies
on the one hand further research on the topic and on
the other to take the risk to intervene even when un-
certainty still remains about its effectiveness. The iner-
tia on this field is already too costly and certainly the
early retirement scenario is not going to improve if
nothing is done otherwise. Of course, the decision
should always depend on the budget required to im-
plement a given job vocational program and due
oppor tunity costs. On this regard, taking advantage of
geo graphically or historically closed stakeholders might
be a key success factor, by sharing costs and leveraging
synergies and economies of scale. For instance, job vo-
cational programs agreed upon by large employers and
the nearest rheumatology department in a certain re-
gion could be a cost-effective starting point – to build
the proof-of-concept of a given protocol and to pilot a
broader national policy targeting early retirement in RD
patients. Surely, such programs, if possible, should go
along with longitudinal prospective studies in order to
measure the occupational outcomes and their levels of
cost-effectiveness. 
In order to increase the likelihood of success of such
interventions, some guidance can be drawn from the
current literature. First, well-planned interventions
should aim different levels (e.g. RD patient, workplace)
and should foster lean communication and alignment
of all involved actors (e.g. rheumatologists, occupa-
tional physicians, employers). A coordinator could in-
tegrate all aspects of such multilevel and multidisci-
plinary intervention in order to better guarantee the
person-environmental fit by orchestrating distinct roles
and responsibilities; second, prioritizing the right pa-
tients can substantially increase the likelihood of suc-
cess of a given intervention. RD patients at risk of job
loss (e.g. longer duration of disease, high self-reported
pain and disability measured by the health assessment
questionnaire) can be prioritized leading to better and
faster occupational outcomes; third, interventions
should consider the patients’ role and include an ele-
ment of patient education, coaching and support to
ena ble them to play an active part in the management
of their condition in the workplace and also improve
their self-efficacy perception. 
Some steps have been taken in Portugal regarding
this issue, namely the Portugal Apto.PT (Fit for Work
Portugal)70, however more political engagement should
take place to ensure impactful nationwide policies and
interventions targeting RD-related retirement. Hope-
fully, this article can also contribute to make politicians
and other relevant decision-makers aware of the rele-
vance of this topic and the possible solutions that can
be, at least partially, replicated in Portugal. 
CORRESPONDENCE TO
Pedro Laires
Sociedade Portuguesa de Reumatologia. 
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